Figure 9

(A) The comparisons of the risk score in TCGA-BLCA patients with treatment outcomes. (B) The boxplot displaying the difference in common immune checkpoint genes between different risk groups. The comparisons of the TIDE score (C), immunotherapy response proportion (D), CD8⁺ T score, (E) MDSC score (F) between different risk groups. The comparison of immunophenotype score (IPS) between different risk groups. (G) CTLA4⁻_PD1⁻, (H) CTLA4⁻_PD1⁺, (I) CTLA4⁺_PD1⁻, (J) CTLA4⁺_PD1⁺. (K) The comparisons of tumor mutational burden (TMB) of patients in different risk groups. (L) The Kaplan–Meier survival curve between the high- and low-TMB groups. (M) Comparison of the differences in immune subtype between different risk groups. (N) The Kaplan–Meier survival curve between the high- and low-risk groups in the IMvigor210 cohort. Predictive value of risk score for immunotherapy response in the IMvigor210 cohort. (O) The percentage of immunotherapy response among risk groups of patients in the IMvigor210 cohort. (P) The percentage of tumor cell (TC) level type among risk groups of patients in the IMvigor210 cohort. (Q) The percentage of immune cell (IC) level type among risk groups of patients in the IMvigor210 cohort. (R) The percentage of immune subtypes among risk groups of patients in the IMvigor210 cohort. Specimens were scored as immunohistochemistry IC0, IC1, IC2, or IC3 if < 1%, ≥ 1% but < 5%, ≥ 5% but < 10%, or ≥ 10% of IC were PD-L1 positive, respectively. Specimens were scored as immunohistochemistry TC0, TC1, TC2, or TC3 if < 1%, ≥ 1% but < 5%, ≥ 5% but < 50%, or ≥ 50% of TC were PD-L1 positive, respectively. ns not significant; *p < 0.05; **p < 0.01; ***p < 0.001.